GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer
Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, Kathleen Nadine Moore, Michel Fabbro, David M O’Malley, Ana Oaknin, Premal Thaker, Amit M Oza, Nicoletta Colombo, David Gershenson, Carol A Aghajanian, Chel Hun Choi, Yeh Chen Lee, Mansoor Raza Mirza, Robert L Coleman, Lauren Cobb, Philipp Harter, Stephanie Lustgarten, Hagop Youssoufian, Susana Banerjee
International Journal of Gynecologic Cancer Oct 2024, ijgc-2024-005919; DOI: 10.1136/ijgc-2024-005919